Dihydroorotate Dehydrogenase Dhodh Inhibitor Pipeline Insight

DelveInsight’s, “Dihydroorotate Dehydrogenase (DHODH) Inhibitor - Pipeline Insight, 2022,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Dihydroorotate Dehydrogenase (DHODH) Inhibitor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

  • Global coverage

Dihydroorotate Dehydrogenase (DHODH) Inhibitor Understanding

Dihydroorotate Dehydrogenase (DHODH) Inhibitor: Overview

Dihydroorotate dehydrogenase (DHODH), a novel enzyme, involved in the biosynthesis of uridine. Dihydroorotate dehydrogenases are grouped into Class 1 and Class 2, according to sequence similarity, subcellular location and substrate preference. This protein is a mitochondrial protein located on the outer surface of the inner mitochondrial membrane (IMM). DHODH enzyme is proven to play an active role in cancer and immunological disorders such as acute myeloid leukemia, RA, multiple sclerosis. Inhibitors of DHODH block the synthesis of pyrimidine-based nucleotides and are known to potentially possess wide applications as chemotherapeutic agents. Suppression of the DHODH enzyme in humans is a proven treatment method for immune disorders, especially cancer, RA (Leflunomide) and multiple sclerosis (Teriflunomide). There are a number of clinical trials underway for COVID19 treatment using DHODH inhibitors.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Dihydroorotate Dehydrogenase (DHODH) Inhibitor R&D. The therapies under development are focused on novel approaches for Dihydroorotate Dehydrogenase (DHODH) Inhibitor.

Dihydroorotate Dehydrogenase (DHODH) Inhibitor Emerging Drugs Chapters

This segment of the Dihydroorotate Dehydrogenase (DHODH) Inhibitor report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.


Dihydroorotate Dehydrogenase (DHODH) Inhibitor Emerging Drugs


IMU-838: Immunic

IMU-838 is a small molecule, oral tablet formulation based investigational drug that inhibits dihydroorotate dehydrogenase (DHODH) enzyme. IMU-838 is under clinical development for the treatment of relapsing-remitting multiple sclerosis, or RRMS, inflammatory bowel disease, or IBD, and other chronic inflammatory and autoimmune diseases. The drug is in Phase II/III clinical evaluation for the treatment of COVID 2019 infections.


PTC 299: PTC Therapeutics

Emvododstat (formerly PTC 299) is an oral, small molecule tablet that inhibits the cellular enzyme DHODH. The drug is in Phase II/III clinical studies for COVID 2019 infections and in Phase I for Acute myeloid leukaemia.

Further product details are provided in the report……..

Dihydroorotate Dehydrogenase (DHODH) Inhibitor: Therapeutic Assessment

This segment of the report provides insights about the different Dihydroorotate Dehydrogenase (DHODH) Inhibitor drugs segregated based on following parameters that define the scope of the report, such as:

  • Major Players working on Dihydroorotate Dehydrogenase (DHODH) Inhibitor

There are approx. 10+ key companies which are developing the Dihydroorotate Dehydrogenase (DHODH) Inhibitor. The companies which have their Dihydroorotate Dehydrogenase (DHODH) Inhibitor drug candidates in the most advanced stage, i.e. Phase II/III include, Immunic

Phases

DelveInsight’s report covers around 10+ products under different phases of clinical development like

  • Late-stage products (Phase III and
  • Mid-stage products (Phase II and
  • Early-stage products (Phase I/II and Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration


Dihydroorotate Dehydrogenase (DHODH) Inhibitor pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Infusion
  • Intradermal
  • Intramuscular
  • Intranasal
  • Intravaginal
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical
  • Molecule Type


Products have been categorized under various Molecule types such as

  • Vaccines
  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Dihydroorotate Dehydrogenase (DHODH) Inhibitor: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Dihydroorotate Dehydrogenase (DHODH) Inhibitor therapeutic drugs key players involved in developing key drugs.


Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Dihydroorotate Dehydrogenase (DHODH) Inhibitor drugs.

Dihydroorotate Dehydrogenase (DHODH) Inhibitor Report Insights

  • Dihydroorotate Dehydrogenase (DHODH) Inhibitor Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Dihydroorotate Dehydrogenase (DHODH) Inhibitor Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

  • How many companies are developing Dihydroorotate Dehydrogenase (DHODH) Inhibitor drugs?
  • How many Dihydroorotate Dehydrogenase (DHODH) Inhibitor drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for Dihydroorotate Dehydrogenase (DHODH) Inhibitor?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Dihydroorotate Dehydrogenase (DHODH) Inhibitor therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Dihydroorotate Dehydrogenase (DHODH) Inhibitor and their status?
  • What are the key designations that have been granted to the emerging drugs?

Introduction

Executive Summary

Dihydroorotate Dehydrogenase (DHODH) Inhibitor: Overview

  • Structure
  • Mechanism of Action

Pipeline Therapeutics

  • Comparative Analysis

Therapeutic Assessment

  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration

Dihydroorotate Dehydrogenase (DHODH) Inhibitor – DelveInsight’s Analytical Perspective

In-depth Commercial Assessment

  • Dihydroorotate Dehydrogenase (DHODH) Inhibitor companies’ collaborations, Licensing, Acquisition -Deal Value Trends

Dihydroorotate Dehydrogenase (DHODH) Inhibitor Collaboration Deals

  • Company-Company Collaborations (Licensing / Partnering) Analysis
  • Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

  • Comparative Analysis

Drug name: Company name

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Mid Stage Products (Phase II/III)

  • Comparative Analysis

IMU-838: Immunic

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Early Stage Products (Phase I/II)

  • Comparative Analysis

PP 001: EyeGate Pharma

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Pre-clinical and Discovery Stage Products

  • Comparative Analysis

MMV-1793609: Medicines for Malaria Venture

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Inactive Products

  • Comparative Analysis

Dihydroorotate Dehydrogenase (DHODH) Inhibitor Key Companies

Dihydroorotate Dehydrogenase (DHODH) Inhibitor Key Products

Dihydroorotate Dehydrogenase (DHODH) Inhibitor- Unmet Needs

Dihydroorotate Dehydrogenase (DHODH) Inhibitor- Market Drivers and Barriers

Dihydroorotate Dehydrogenase (DHODH) Inhibitor- Future Perspectives and Conclusion

Dihydroorotate Dehydrogenase (DHODH) Inhibitor Analyst Views

Dihydroorotate Dehydrogenase (DHODH) Inhibitor Key Companies

Appendix

List of Table

Table 1: Total Products for Dihydroorotate Dehydrogenase (DHODH) Inhibitor

Table 2: Late Stage Products

Table 3: Mid Stage Products

Table 4: Early Stage Products

Table 5: Pre-clinical & Discovery Stage Products

Table 6: Assessment by Product Type

Table 7: Assessment by Stage and Product Type

Table 8: Assessment by Route of Administration

Table 9: Assessment by Stage and Route of Administration

Table 10: Assessment by Molecule Type

Table 11: Assessment by Stage and Molecule Type

Table 12: Inactive Products

List of Figures

Figure 1: Total Products for Dihydroorotate Dehydrogenase (DHODH) Inhibitor

Figure 2: Late Stage Products                              

Figure 3: Mid Stage Products

Figure 4: Early Stage Products

Figure 5: Preclinical and Discovery Stage Products

Figure 6: Assessment by Product Type

Figure 7: Assessment by Stage and Product Type

Figure 8: Assessment by Route of Administration

Figure 9: Assessment by Stage and Route of Administration

Figure 10: Assessment by Molecule Type

Figure 11: Assessment by Stage and Molecule Type

Figure 12: Inactive Products    

• Sanofi

• Immunic

• PTC Therapeutics

• Clear Creek Bio

• EyeGate Pharma

• ASLAN Pharmaceuticals

• Medicines for Malaria Venture

Forward to Friend

Need A Quote